Keywords
Immunohistochemistry (IHC)
ALK
PD-L1
EGFR
How to Cite
Abstract
Introduction: Lung cancer, with about 2.2 million new cases and 1.8 million deaths, is the second most commonly diagnosed cancer and the leading cause of cancer death in 2020. Immunohistochemistry (IHC) now is used not only to diagnose and classify lung tumors into subtypes, but also to determine the eligibility of patients for different molecular-targeted therapies.
Objectives : Study of ALK, EGFR and PD-L1 mutations in Pulmonary Carcinomas through immunohistochemistry examinations to help determine the prognosis and cases that may benefit from target therapy. Detection of possible links between ALK, EGFR, PD-L1 and other variables such as age, sex, histological entity and degree of tumor differentiation.
Materials and Methodology: The study is retrospective and includes 266 patients diagnosed with lung cancer who underwent biopsy at the American Hospital in the period 2016-2020. Tissues obtained were subjected to IHC examination using antibodies against factors EGFR, ALK, PD-L1, etc.
Results: The study showed that out of 266 patients, 24% of lung cancer cases are females and 76% are males. The average age was 61.8 years. No statistically significant relationship was found between ALK, PD-L1 and EGFR with variables such as age, gender and degree of differentiation of adenocarcinomas. No significant link was found between ALK and PD-L1 and the histological entity, but a significant link was found between EGFR and histological type of pulmonary carcinomas.
Conclusions : Lung cancer is one of the most common cancers, found mainly in men, but also in women. Nowadays, IHC helps not only to diagnose lung cancer, but also to determine patients who can respond to target therapy and their prognosis. Therefore, the use of IHC to detect ALK, EGFR, PDL-1 mutations and their links to patient characteristics is becoming increasingly necessary.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
Inamura K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers (Basel). 2018;10(3):72. Published 2018 Mar 14. doi:10.3390/cancers10030072
Qin A, Gadgeel S. The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. Target Oncol. 2017;12(6):709-718. doi:10.1007/s11523-017-0526-1
Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. TherAdv Med Oncol. 2016;8(1):32-47. doi:10.1177/1758834015617355
Du X, Shao Y, Qin HF, Tai YH, Gao HJ. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018;9(4):423-430. doi:10.1111/1759-7714.12613
Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. ClinAdvHematolOncol. 2014;12(7):429-439.
Alshareef A. Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers. Cancers (Basel). 2017;9(11):148. Published 2017 Oct 28. doi:10.3390/cancers9110148
Chung C. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics. Journal of Oncology Pharmacy Practice. 2016;22(3):461-476. doi:10.1177/1078155215577810
Reddi HV. Mutations in the EGFR pathway. American Association for Clinical Chemistry. Updated October 1, 2013.
Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48-51.
Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials. 2006 Jan;1(1):1-13.
doi: 10.2174/157488706775246157. PMID: 18393776.
Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48-51.
Teixidó C, Vilariño N, Reyes R, Reguart N. PD-L1 expression testing in non-small cell lung cancer. TherAdv Med Oncol. 2018 Apr 11; 10:1758835918763493. doi: 10.1177/1758835918763493 PMID: 29662547; PMCID: PMC5898658.
Wu X, Gu Z, Chen Y, et al. Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019; 17:661-674. Published 2019 May 23. doi: 10.1016/j.csbj 2019.03.006
Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol. 2017; 8: 561. Published 2017 Aug 23. doi:10.3389/fphar.2017.00561
Tsao M. S., Hirsch F. R., Yatabe Y., The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer, 2nd edition.
Mok T. S., Carbone D. P., Hirsch F. R., IASLC Atlas of EGFR Testing in Lung Cancer.
Tsao M. S., Kerr K. M., Dacic S., Yatabe Y., Hirsch F. R., The IASLC Atlas of PD-L1 Testing in Lung Cancer, 55-63
Levy M, Lyon L, Barbero E, Wong J, Suga M, Sam D, Pan M. Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma. Med Sci (Basel). 2017 Dec 11;5(4):34. doi: 10.3390/medsci5040034. PMID: 29232915; PMCID: PMC5753663.
Hofman V, Lassalle S, Bence C, et al. Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? Cancers (Basel). 2018;10(3):70. Published 2018 Mar 13. doi:10.3390/cancers10030070
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.